Articles tagged "Cytomeglovirus"

2019 American Transplant Congress
Using a Commercially Available Assay That Measures Cytomegalovirus-Specific CD4+ and CD8+ T-cell Immunity to Predict Clinically Significant Cytomegalovirus Events in Solid Organ Transplant Recipients
R. Rogers¹, K. Saharia², A. Chandorkar², Z. Weiss³, D. Farmakiotis¹
¹Infectious Diseases, Brown University, Providence, RI, ²Infectious Diseases, University of Maryland, Baltimore, MD, ³Internal Medicine, Brown University, Providence, RI
*Purpose: To assess the diagnostic performance and clinical utility of the Viracor CMV T-cell Immunity Panel (CMV-TCIP), which measures both CMV-specific Cd4+ and Cd8+ T-cell…
2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman¹, S. G. Westphal², F. Qiu³, D. Bremers⁴, D. Florescu⁵
¹College of Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Donate Life, Nebraska Medicine, Omaha, NE, ⁵Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…
2019 American Transplant Congress
Effect of Donor-Recipient Serologic CMV Matching on 1-Year Post-Lung Transplant Outcomes
H. Ehrenfeld, M. Manson, R. Yau
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Cytomegalovirus (CMV) poses significant risks and complications in solid organ transplant (SOT) patients. The current CMV guidelines acknowledge CMV serologic mismatch transplants contribute to…
2018 American Transplant Congress
Kidney Transplant Allocation with CMV Seromatching Reduces CMV Infection without Affecting Wait Times
A. Narra,¹ L. Strasfeld,² D. Basuli,¹ M. Stack,¹ E. Langewisch,³ A. Olyaei,¹ D. Norman,^1,4 J. Lockridge.^1,4
¹Transplant Nephrology, Oregon Health and Science University, Portland, OR; ²Infectious Diseases, OHSU, Portland, OR; ³Transplant Nephrology, University of Nebraska Medical Center, Omaha, NE; ⁴Transplant Nephrology, Portland VA, Portland, OR.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in kidney transplant recipients.A pre-transplant allocation strategy by matching deceased kidney donors and recipients…
2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
B. Banas,¹ D. Steubl,² L. Renders,² D. Chittka,¹ M. Banas,¹ T. Wekerle,³ M. Koch,⁴ O. Witzke,⁵ A. Muehlfeld,⁶ C. Sommerer,⁷ A. Habicht,⁸ C. Hugo,⁹ T. Huenig,¹⁰ M. Lindemann,⁵ T. Schmidt,¹¹ A. Rascle,¹¹ S. Barabas,¹¹ L. Deml,¹¹ R. Wagner,^1,11 B. Kraemer,¹² B. Krueger.¹²
¹University Clinic, Regensburg, Germany; ²Clinic rechts der Isar TUM, Munich, Germany; ³Medical University, Vienna, Austria; ⁴University Clinic, Hamburg-Eppendorf, Germany; ⁵University Hospital, Essen, Germany; ⁶Uniklinik RWTH, Aachen, Germany; ⁷University Hospital, Heidelberg, Germany; ⁸LMU Medical Center, Munich, Germany; ⁹University Hospital, Dresden, Germany; ¹⁰University Hospital, Wuerzburg, Germany; ¹¹Lophius Biosciences, Regensburg, Germany; ¹²UMM Uni. Heidelberg, Mannheim, Germany.
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
2018 American Transplant Congress
A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients
S. Shaikh, N. Panek, J. Park.
MedStar Georgetown University Hospital, Washington DC; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago; Michigan Medicine, Ann Arbor.
Objective: The FDA-approved pediatric indication of valganciclovir (VGCV) is limited to cytomegalovirus (CMV) prophylaxis in heart and kidney transplants. The recommended regimen is a daily…
2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
A. Kraljevic, C. D'Agostino, C. Kane, K. Cunningham, A. Shetty, C. Richardson.
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…
2018 American Transplant Congress
Financial Impact of Testing Standardization for Solid Organ Transplant Recipients
S. Ugolini,² L. Dranow,¹ P. Sadler,² M. Berry,² J. Stehlik,¹ S. Drakos,¹ J. Nativi,¹ E. Gilbert,¹ S. McKeller,¹ A. Koliopoulou,¹ M. Yin,¹ E. Davis,² C. Selzman,¹ O. Wever-Pinzon.¹
¹Division of Cardiology, University of Utah Health, Salt Lake City, UT; ²Transplant Service Line, University of Utah Health, Salt Lake City, UT.
Background: Infection and bone marrow suppression surveillance is common practice in transplant recipients. Ordering of inappropriate lab tests can lead to repetitive blood draws, higher…
2018 American Transplant Congress
Evaluation of Risk Factors for Progression of Low Level CMV Viremia in Solid Organ Transplant Recipients
Y. Natori, A. Humar, A. Alghamdi, D. Kumar.
Multi Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Background: Low level CMV viremia is common, and may either progress to higher viral loads that require therapy, or may spontaneously resolve. The clinical predictors…
2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
M. Jarque,¹ H. Kaminski,² L. Couzi,² E. Crespo,¹ J. Déchanet-Merville,³ S. Luque,¹ N. Montero,⁴ M. Pascual,⁵ O. Manuel,^5,6 P. Merville,² O. Bestard.^1,4
¹Nephrology Lab, IDIBELL, Barcelona, Spain; ²Nephrology Dep, Hôpital Pellegrin, Bordeaux, France; ³National Center of Scientific Research, Bordeaux, France; ⁴Nephrology Dep, Bellvitge Hospital, Barcelona, Spain; ⁵Transplantation Center, Lausanne Hospital, Lausanne, Switzerland; ⁶Infectious Diseases Dep, Lausanne Hospital, Lausanne, Switzerland.
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…